Previous 10 | Next 10 |
Allogene Therapeutics (NASDAQ: ALLO ) initiated with Market Perform rating and $37 (36% upside) price target at JMP Securities. More news on: Allogene Therapeutics, Inc., CorMedix, Inc., Fortress Biotech, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
YARDLEY, Pa., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that results of the Phase 3 EXHANCE-3 trial were published in the peer-reviewed journal ...
YARDLEY, Pa., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business upda...
Shares of Optinose (NASDAQ: OPTN) were down 14% at 11:47 a.m. EST today after the company priced its previously announced secondary offering at $9.75 per share. On Wednesday, shares closed at $11.41, and with that kind of discount, a decline today was all but inevitable. Optinose rai...
Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...
OptiNose (NASDAQ: OPTN ) -15% on report of offering at 14.6% discount. More news on: OptiNose, Inc., BJ's Wholesale Club Holdings, Inc., Baozun Inc., Stocks on the move, Read more ...
YARDLEY, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a pub...
OptiNose (NASDAQ: OPTN ) is off 9.7% postmarket after a report that an equity offering (from the company and shareholders) will amount to $50M in shares. More news on: OptiNose, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Gainers: NUAN +8.3% . KRTX +3.7% . NNBR +3.7% . TIF +3.4% . JACK +2.9% . More news on: Nuance Communications, Inc., Karuna Therapeutics, Inc., NN, Inc., Stocks on the move, Read more ...
YARDLEY, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it and certain selling stockholders intend to offer and sell shares of its common stock in...
News, Short Squeeze, Breakout and More Instantly...
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE ® (fluticasone propionate) has been added to Express Scripts’ nationa...
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C...
2024-05-15 10:30:03 ET Lake Street analyst issues BUY recommendation for OPTN on May 15, 2024 08:43AM ET. The previous analyst recommendation was Buy. OPTN was trading at $1.13 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...